These data suggest that high dosage of ETV4 expression is required to drive an ETS-mediated oncogenic transcriptional program but simultaneously induces Trp53- and p53-associated senescence, which likely limit prostate cancer development and progression from mPIN in ETV4AAA-expressing prostate. The gene discussed is TP53; the disease is prostate carcinoma.